News

IRVINE, Calif.–(BUSINESS WIRE)–GlyTR Therapeutics, Inc. is pleased to announce it has been awarded an approximately $300,000 grant from The National Cancer Institute (NCI), National Institute of Health (NIH) thru the Small Business Technology Transfer Program. This grant award comes on the heels of a $3.4 million grant on its Glycan dependent T cell Recruiter (GlyTR – pronounced ‘glitter’) technology received in September from the Beau Biden Cancer Moonshot initiative at NCI. The new funding will support the company’s development of highly novel cancer immunotherapies that trigger the… Read More »GlyTR Therapeutics ‘Cancer Moonshot’ Technology Receives Second Grant from the National Cancer Institute

Novel GlyTR technology may markedly broaden the types of cancers sensitive to immunotherapy Irvine, Calif. – September 27, 2018 – UCI School of Medicine researchers have been awarded a $3.4 million grant by the National Cancer Institute (NCI) as part of the Beau Biden Cancer Moonshot initiative. The funding will support efforts to provide proof of principal data for an entirely new class of cancer killing immunotherapeutics with the potential to treat highly diverse types of cancer, from leukemia to breast cancer. Principal investigator, Michael… Read More »UCI awarded $3.4M NIH “Cancer Moonshot” grant to study potential breakthrough in cancer immunotherapy